Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism

Spyridoula Maraka, Naykky M. Singh Ospina, Derek T. O'Keeffe, Rene Rodriguez-Gutierrez, Ana E. Espinosa De Ycaza, Chung Il Wi, Young J Juhn, Charles C. Coddington, Victor Manuel Montori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Uncontrolled hypothyroidism has been associated with an increased risk of adverse pregnancy outcomes. We aimed to assess the effectiveness of increasing levothyroxine (LT4) dose on reducing the risk of adverse outcomes for pregnant women with TSH level greater than the recommended 1st trimester limit. Design, Patients, Measurements: We reviewed the electronic medical records of pregnant women evaluated from January 2011 to December 2013, who had history of LT4-treated hypothyroidism and were found to have TSH > 2·5 mIU/l in 1st trimester. Women were divided into two groups: group A – LT4 dose was increased within two weeks from the TSH test, group B – LT4 dose remained stable. We compared the frequency of pregnancy loss (primary outcome) and other prespecified pregnancy-related adverse outcomes between groups. Results: There were 85 women in group A (median TSH: 5·0, interquartile range 3·8–6·8 mIU/l) and 11 women in group B (median TSH: 4·5, interquartile range 3·2–4·9 mIU/l). The groups were not different in baseline clinical and socioeconomic characteristics. The mean interval between TSH test and LT4 dose increase was 4·5 (SD 4·6) days. Pregnancy loss was significantly lower in group A (2/85, 2·4%) vs group B (4/11, 36·4%) (P = 0·001). Other pregnancy-related adverse outcomes were similar between groups. Conclusions: Increasing LT4 dose for women with uncontrolled hypothyroidism in the 1st trimester of pregnancy was associated with a decreased risk of pregnancy loss. Given the limitations of our study, this association awaits further confirmation from larger studies.

Original languageEnglish (US)
Pages (from-to)150-155
Number of pages6
JournalClinical Endocrinology
Volume86
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pregnancy Outcome
Hypothyroidism
Thyroxine
Pregnancy
Pregnant Women
Pregnancy Trimesters
Electronic Health Records

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Maraka, S., Singh Ospina, N. M., O'Keeffe, D. T., Rodriguez-Gutierrez, R., Espinosa De Ycaza, A. E., Wi, C. I., ... Montori, V. M. (2017). Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism. Clinical Endocrinology, 86(1), 150-155. https://doi.org/10.1111/cen.13168

Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism. / Maraka, Spyridoula; Singh Ospina, Naykky M.; O'Keeffe, Derek T.; Rodriguez-Gutierrez, Rene; Espinosa De Ycaza, Ana E.; Wi, Chung Il; Juhn, Young J; Coddington, Charles C.; Montori, Victor Manuel.

In: Clinical Endocrinology, Vol. 86, No. 1, 01.01.2017, p. 150-155.

Research output: Contribution to journalArticle

Maraka, S, Singh Ospina, NM, O'Keeffe, DT, Rodriguez-Gutierrez, R, Espinosa De Ycaza, AE, Wi, CI, Juhn, YJ, Coddington, CC & Montori, VM 2017, 'Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism', Clinical Endocrinology, vol. 86, no. 1, pp. 150-155. https://doi.org/10.1111/cen.13168
Maraka S, Singh Ospina NM, O'Keeffe DT, Rodriguez-Gutierrez R, Espinosa De Ycaza AE, Wi CI et al. Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism. Clinical Endocrinology. 2017 Jan 1;86(1):150-155. https://doi.org/10.1111/cen.13168
Maraka, Spyridoula ; Singh Ospina, Naykky M. ; O'Keeffe, Derek T. ; Rodriguez-Gutierrez, Rene ; Espinosa De Ycaza, Ana E. ; Wi, Chung Il ; Juhn, Young J ; Coddington, Charles C. ; Montori, Victor Manuel. / Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism. In: Clinical Endocrinology. 2017 ; Vol. 86, No. 1. pp. 150-155.
@article{7b1c917ae2804216bc2f0a64bb32b0b5,
title = "Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism",
abstract = "Objective: Uncontrolled hypothyroidism has been associated with an increased risk of adverse pregnancy outcomes. We aimed to assess the effectiveness of increasing levothyroxine (LT4) dose on reducing the risk of adverse outcomes for pregnant women with TSH level greater than the recommended 1st trimester limit. Design, Patients, Measurements: We reviewed the electronic medical records of pregnant women evaluated from January 2011 to December 2013, who had history of LT4-treated hypothyroidism and were found to have TSH > 2·5 mIU/l in 1st trimester. Women were divided into two groups: group A – LT4 dose was increased within two weeks from the TSH test, group B – LT4 dose remained stable. We compared the frequency of pregnancy loss (primary outcome) and other prespecified pregnancy-related adverse outcomes between groups. Results: There were 85 women in group A (median TSH: 5·0, interquartile range 3·8–6·8 mIU/l) and 11 women in group B (median TSH: 4·5, interquartile range 3·2–4·9 mIU/l). The groups were not different in baseline clinical and socioeconomic characteristics. The mean interval between TSH test and LT4 dose increase was 4·5 (SD 4·6) days. Pregnancy loss was significantly lower in group A (2/85, 2·4{\%}) vs group B (4/11, 36·4{\%}) (P = 0·001). Other pregnancy-related adverse outcomes were similar between groups. Conclusions: Increasing LT4 dose for women with uncontrolled hypothyroidism in the 1st trimester of pregnancy was associated with a decreased risk of pregnancy loss. Given the limitations of our study, this association awaits further confirmation from larger studies.",
author = "Spyridoula Maraka and {Singh Ospina}, {Naykky M.} and O'Keeffe, {Derek T.} and Rene Rodriguez-Gutierrez and {Espinosa De Ycaza}, {Ana E.} and Wi, {Chung Il} and Juhn, {Young J} and Coddington, {Charles C.} and Montori, {Victor Manuel}",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/cen.13168",
language = "English (US)",
volume = "86",
pages = "150--155",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effects of increasing levothyroxine on pregnancy outcomes in women with uncontrolled hypothyroidism

AU - Maraka, Spyridoula

AU - Singh Ospina, Naykky M.

AU - O'Keeffe, Derek T.

AU - Rodriguez-Gutierrez, Rene

AU - Espinosa De Ycaza, Ana E.

AU - Wi, Chung Il

AU - Juhn, Young J

AU - Coddington, Charles C.

AU - Montori, Victor Manuel

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: Uncontrolled hypothyroidism has been associated with an increased risk of adverse pregnancy outcomes. We aimed to assess the effectiveness of increasing levothyroxine (LT4) dose on reducing the risk of adverse outcomes for pregnant women with TSH level greater than the recommended 1st trimester limit. Design, Patients, Measurements: We reviewed the electronic medical records of pregnant women evaluated from January 2011 to December 2013, who had history of LT4-treated hypothyroidism and were found to have TSH > 2·5 mIU/l in 1st trimester. Women were divided into two groups: group A – LT4 dose was increased within two weeks from the TSH test, group B – LT4 dose remained stable. We compared the frequency of pregnancy loss (primary outcome) and other prespecified pregnancy-related adverse outcomes between groups. Results: There were 85 women in group A (median TSH: 5·0, interquartile range 3·8–6·8 mIU/l) and 11 women in group B (median TSH: 4·5, interquartile range 3·2–4·9 mIU/l). The groups were not different in baseline clinical and socioeconomic characteristics. The mean interval between TSH test and LT4 dose increase was 4·5 (SD 4·6) days. Pregnancy loss was significantly lower in group A (2/85, 2·4%) vs group B (4/11, 36·4%) (P = 0·001). Other pregnancy-related adverse outcomes were similar between groups. Conclusions: Increasing LT4 dose for women with uncontrolled hypothyroidism in the 1st trimester of pregnancy was associated with a decreased risk of pregnancy loss. Given the limitations of our study, this association awaits further confirmation from larger studies.

AB - Objective: Uncontrolled hypothyroidism has been associated with an increased risk of adverse pregnancy outcomes. We aimed to assess the effectiveness of increasing levothyroxine (LT4) dose on reducing the risk of adverse outcomes for pregnant women with TSH level greater than the recommended 1st trimester limit. Design, Patients, Measurements: We reviewed the electronic medical records of pregnant women evaluated from January 2011 to December 2013, who had history of LT4-treated hypothyroidism and were found to have TSH > 2·5 mIU/l in 1st trimester. Women were divided into two groups: group A – LT4 dose was increased within two weeks from the TSH test, group B – LT4 dose remained stable. We compared the frequency of pregnancy loss (primary outcome) and other prespecified pregnancy-related adverse outcomes between groups. Results: There were 85 women in group A (median TSH: 5·0, interquartile range 3·8–6·8 mIU/l) and 11 women in group B (median TSH: 4·5, interquartile range 3·2–4·9 mIU/l). The groups were not different in baseline clinical and socioeconomic characteristics. The mean interval between TSH test and LT4 dose increase was 4·5 (SD 4·6) days. Pregnancy loss was significantly lower in group A (2/85, 2·4%) vs group B (4/11, 36·4%) (P = 0·001). Other pregnancy-related adverse outcomes were similar between groups. Conclusions: Increasing LT4 dose for women with uncontrolled hypothyroidism in the 1st trimester of pregnancy was associated with a decreased risk of pregnancy loss. Given the limitations of our study, this association awaits further confirmation from larger studies.

UR - http://www.scopus.com/inward/record.url?scp=84994493195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994493195&partnerID=8YFLogxK

U2 - 10.1111/cen.13168

DO - 10.1111/cen.13168

M3 - Article

VL - 86

SP - 150

EP - 155

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 1

ER -